Dolutegravir in antiretroviral-naive adults with HIV-1

2013162 citationsJournal Articlehybrid Open Access

Authors

Hans-Jürgen Stellbrink · Infektionsmedizinisches Centrum Hamburg

Jacques Reynes · Hôpital Gui de Chauliac

Adriano Lazzarin

Eugene Voronin · Infectious Clinical Hospital No. 1

Federico Pulido · Research Institute Hospital 12 de Octubre

Franco Felizarta

Steve Almond · GlaxoSmithKline (Canada)

Marty St. Clair

Abstract

Throughout the 96 weeks of the SPRING-1 study, DTG demonstrated sustained efficacy and favorable safety/tolerability in treatment-naive individuals with HIV-1.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: AIDS

Volume 27, Issue 11, pp. 1771-1778

DOI: 10.1097/qad.0b013e3283612419

Field-Weighted Citation Impact: 9.03